Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Conditions:   NSCLC;   HNSCC
Interventions:   Drug: Eftilagimod alpha;   Drug: Pembrolizumab
Sponsors:   Immutep S.A.;   Merck Sharp & Dohme Corp.
Not yet recruiting

https://ift.tt/2MilKY0